



UNIVERSITY OF LEEDS

This is a repository copy of *Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/181681/>

Version: Supplemental Material

---

**Article:**

Guren, MG, Sebag-Montefiore, D [orcid.org/0000-0002-5978-9259](https://orcid.org/0000-0002-5978-9259), Franco, P et al. (6 more authors) (2021) Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. *Clinical Colorectal Cancer*, 20 (4). pp. 279-287. ISSN 1533-0028

<https://doi.org/10.1016/j.clcc.2021.09.006>

---

© 2021, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Table 2** Randomised trials of chemoradiotherapy for anal cancer

Trial	Comparison	Disease-related outcomes				Acute toxicities Grade 3-4				Late toxicities Skin + GI + GU + others (%)
		5-year LR control (%)	5-year OS (%)	5-year CFS (%)	DFS (%)	Hematologic (%)	Skin (%)	GI (%)	GU (%)	
ACT I	RT + 5-FU/MMC vs RT alone	68 vs 43	58 vs 53	47 vs 37		NR grade	Severe: 17 vs 14	Severe: 5 vs 2	1 vs 0	Skin: 21 vs 18 Anorectal: 29 vs 27 GU: 4 vs 4 Ulcers/radionecrosis: 8 vs 6
EORTC 22861	RT + 5-FU/MMC vs RT alone	68 vs 51	58 vs 53	72 vs 40		NR	60 vs 50	Diarrhea: 20 vs 8	NR	Skin ulceration: 6 vs 4
RTOG 87-04	RT + 5-FU/MMC vs RT + 5-FU	84 vs 66 (4 years)	71 vs 59	76 vs 67		18 vs 3	NR			G4-G5 late toxicity: 5 vs 1
RTOG 98-11	RT + 5-FU/MMC vs ICT (5-FU/DDP) + RT + 5-FU/DDP	80 vs 74	78 vs 71	72 vs 65	68 vs 58	62 vs 42	49 vs 41	37 vs 47	3 vs 3	Skin: G3-G4: 4 vs 2 GI: G3-4: 3 vs 2 Other: G3-4: 13 vs 11
ACCORD 03	ICT (5-FU/DDP) + RT and 5-FU/DDP vs RT and 5-FU/DDP	80 vs 81	83 vs 79	77 vs 75	72 vs 65	19 vs 12	3 vs 3	9 vs 11	NR	G3-4: Diarrhoea 5 Incontinence: 15 Ulceration/fistula: 12 Bleeding: 25 Anal pain: 12
ACT II	RT + 5-FU/MMC vs RT + 5-FU/DDP + maintenance DDP	NR	82 vs 83 (3 years)	68 vs 70	73 vs 73 (PFS 3 years)	26 vs 16	48 vs 47	16 vs 18	1 vs 2	NA

Legend: 5-FU: 5-fluorouracil; MMC: Mytomicin-C; DDP: cisplatin; RT: radiotherapy; ICT: induction chemotherapy; LR: locoregional; OS: overall survival; CFS: colostomy-free survival; DFS: disease-free survival; PFS: progression-free survival; GI: gastrointestinal; GU: genitourinary; NR: not reported.